Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akoya Biosciences (AKYA)
NASDAQ:AKYA
Holding AKYA?
Track your performance easily
AKYA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.88 - $6.31
Previous Close$2.49
Volume365.65K
Average Volume (3M)230.18K
Market Cap
$123.41M
Enterprise Value$172.44M
Total Cash (Recent Filing)$35.90M
Total Debt (Recent Filing)$84.92M
Price to Earnings (P/E)―
Beta3.07
Next Earnings
Mar 10, 2025EPS Estimate
-$0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.18
Shares Outstanding49,563,386
10 Day Avg. Volume674,261
30 Day Avg. Volume230,184
Standard Deviation0.17
R-Squared0.12
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)8.89
Price to Sales (P/S)1.42
Price to Cash Flow (P/CF)-3.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.99
Enterprise Value/Gross Profit3.06
Enterprise Value/Ebitda-3.57
Forecast
1Y Price Target
$3.63Price Target Upside45.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Akoya Biosciences News
PremiumCompany Announcements
Akoya Biosciences Reports Q3 2024 Financial Results
Bulls Say, Bears Say
Bulls Say
Clinical Opportunities And Long-Term GrowthThe analyst remains optimistic that AKYA's performance will improve, with the company's clinical opportunity adding upside for the long term.
Product Launch And Revenue GrowthAkoya remains confident it can return to revenue growth due to the launch of new products and a robust clinical trial pipeline.
Strategic AlternativesThe company is actively evaluating a range of strategic alternatives to identify the best path forward for sustainable growth, profitability, and long-term success.
Bears Say
EarningsThe company reported third-quarter results that were significantly lower than estimates, primarily due to extended sales cycles and limited capital equipment funding.
Financial GuidanceThe company has significantly lowered its 2024 revenue guidance and no longer anticipates achieving cash flow breakeven in the fourth quarter of 2024.
Sales PerformanceTotal revenue fell short of estimates as shipments were impacted by a lack of funding among customers, particularly affecting sales of capital equipment in the life science tools sector.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
AKYA FAQ
What was Akoya Biosciences’s price range in the past 12 months?
Akoya Biosciences lowest stock price was $1.88 and its highest was $6.31 in the past 12 months.
What is Akoya Biosciences’s market cap?
Currently, no data Available
When is Akoya Biosciences’s upcoming earnings report date?
Akoya Biosciences’s upcoming earnings report date is Mar 10, 2025 which is in 78 days.
How were Akoya Biosciences’s earnings last quarter?
Akoya Biosciences released its earnings results on Nov 14, 2024. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.2 by -$0.01.
Is Akoya Biosciences overvalued?
According to Wall Street analysts Akoya Biosciences’s price is currently Undervalued.
Does Akoya Biosciences pay dividends?
Akoya Biosciences does not currently pay dividends.
What is Akoya Biosciences’s EPS estimate?
Akoya Biosciences’s EPS estimate is -$0.16.
How many shares outstanding does Akoya Biosciences have?
Akoya Biosciences has 49,563,385 shares outstanding.
What happened to Akoya Biosciences’s price movement after its last earnings report?
Akoya Biosciences reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.2. Following the earnings report the stock price went down -23.003%.
Which hedge fund is a major shareholder of Akoya Biosciences?
Among the largest hedge funds holding Akoya Biosciences’s share is Fisher Asset Management LLC. It holds Akoya Biosciences’s shares valued at N/A.
---
Akoya Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.63 (45.78% Upside)
$3.63 (45.78% Upside)
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.13%
12-Months-Change
Fundamentals
Return on Equity
-153.34%
Trailing 12-Months
Asset Growth
-26.67%
Trailing 12-Months
Company Description
Akoya Biosciences
Akoya Biosciences Inc is an an innovative life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery and clinical research. It offers the most comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications.
---
AKYA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a challenging quarter for Akoya Biosciences, with significant revenue declines and underperformance in instrument sales due to market constraints. However, improvements in operational efficiencies and strategic advancements in the clinical pipeline provide a positive outlook for long-term growth.Read More>---
AKYA Stock 12 Month Forecast
Average Price Target
$3.63
▲(45.78% Upside)
Technical Analysis
Best Analysts Covering AKYA
1 Year
1 Year Success Rate
2/16 ratings generated profit
1 Year Average Return
-30.43%
assigned a buy rating last month
Copying David Westenberg's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -30.43% per trade.
---